title: Alveolar echinococcosis: Em2plus-ELISA and Em18-western blots for follow-up after treatment with albendazole.
abstract: Eleven cases of alveolar echinococcosis (Echinococcus multilocularis infection) with non-resectable lesions but treated with albendazole for 17 to 69 months were followed-up clinically and serologically for 4.5-11.5 years. Based on the clinical outcome and computerized tomography (CT) scanning, they were divided into 4 groups of 2 cured cases, 5 stabilized cases, 3 cases with recurrences, and one treatment failure. Forty-seven sequentially collected sera from the 11 cases were analysed by sequential enzyme-linked immunosorbent assay (ELISA) using Em2plus antigen (Em2plus-ELISA) and Western blotting to detect antibody response against Em18 (Em18-Western blots). The antibody levels in one of the cured and 2 of the stabilized cases fell below the cut-off level in the Em2plus-ELISA 4.5-6 years after effective treatment, whereas all other cases, including 2 of those with recurrences, showed large reductions initially but increased again during the follow-up period. Em18-Western blots of the 2 cured cases and 2 of the stabilized cases became negative. IgG subclasses with responses against Em18 which fell to zero included IgG1 (2), IgG3 (one) and IgG4 (one). All other cases showed no decrease in antibody response against Em18. There were, in general, reasonably reliable correlations between the success or failure of chemotherapy and antibody responses by Em2plus-ELISA and Em18-Western blots. These results suggest that both Em2plus-ELISA and Em18-Western blot are potentially useful in evaluating and predicting the efficacy of chemotherapy.
authors.affiliation: Institute of Infectious and Parasitic Diseases, First Affiliated Hospital, Chongqing University of Medical Sciences, People's Republic of China.
authors.forename: L
authors.initials: L
authors.lastname: Ma
authors.forename: A
authors.initials: A
authors.lastname: Ito
authors.forename: Y H
authors.initials: YH
authors.lastname: Liu
authors.forename: X G
authors.initials: XG
authors.lastname: Wang
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Yao
authors.forename: D G
authors.initials: DG
authors.lastname: Yu
authors.forename: Y T
authors.initials: YT
authors.lastname: Chen
mesh_terms: D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000097:blood; D000923:Anticestodal Agents / Q000627:therapeutic use*; D015153:Blotting, Western; D004445:Echinococcosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000909:Antibodies, Helminth; D000923:Anticestodal Agents; D007074:Immunoglobulin G; D015766:Albendazole